Nationwide multicenter prospective study on the long-term effects of bromocriptine for parkinson’s disease

European Neurology

Volumn 38, Issue , 1997, Pages 37-49

  Ogawa, Norio ^a   Kanazawa, Ichiro ^b   Kowa, Hisayuki ^c   Kuno, Sadako ^d   Mizuno, Yoshikuni ^e   Tashiro, Kunio ^f   Yanagisawa, Nobuo ^g  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KITASATO UNIVERSITY HOSPITAL   (Japan)

^d UTANO NATIONAL HOSPITAL   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

^g SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse reactions; Bromocriptine; Dopamine agonist; Dyskinesia; Early introduction; Long term treatment; Wearing off phenomenon

Indexed keywords

ANTIPARASITIC AGENT; BROMOCRIPTINE; LEVODOPA;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LEVODOPA; LONG-TERM CARE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE;

EID: 0030666751     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113482     Document Type: Article

References (37)

1. Munler MO, Sharpies NS, Tycc GM, Darley FL: Patterns of dystonia ('I-D-F and 'D-I-D') in response to -dopa therapy for Parkinson's disease, Mayo Clin Proc 1977;52:163-174.
2. Marsdcn CD, Parkes JD: 'On-ofF effects in patients with Parkinson's disease on chronic levodopa therapy, Lancet 1976;1:292-296.
3. Pinder RM, Brogden RN, Sawcr PR, Speight TM, Avcrly GS: Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of parkinsonism, Drugs 1976;11:329-377.
4. Basma AN, Morris EJ, Nicklas WJ, Gcllcr HM: -DOPA cytotoxicity to PC 12 cells in culture is via its autoxidation, J Neurochcm 1995:64: 825-832.
5. Ogawa N, Asanuma M, Rondo Y, Kawada Y, Yamamoto M, Mori A: Differential effects of chronic ¿-DOPA treatment on lipid peroxidation in the mouse brain with or without pre-treatment of 6-hydroxydopamine, Neurosci Lett 1994:171:55-58.
6. Pardo B, Mena MA, Casarcjos MJ, Paino CL, De Yebens JG: Toxic effects of ¿-DOPA on mesencephalic cell cultures: Protection with antioxidants, Brain Res 1995:682:133-143.
7. Walkinshaw G, Waters CM: Induction of apoptosis in catecholaminergic PC 12 cells by ¿-DOPA: Implication for the treatment of Parkinson’s disease, J Clin Invest 1995:95:2458-2464.
8. Nakanishi T, Iwata M, Goto I, Kanazawa I, Kowa H, Manncn T, Mizuno Y, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N: Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of Parkinson's disease: Final report, Eur Neurol 1992:32(suppl 1):9-22.
9. Nakanishi T, Kanazawa I, Iwata M, Goto I, Kowa H, Mannen T, Mizuno Y, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N: Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: Analysis on the maintenance and the change of the original mode of treatment, Eur Neurol 1992;32(suppl l):23-29.
10. Kuno S: Progress note on Japanese multicenter bromocriptine monotherapy, Eur Neurol 1993: 33(suppl 1):3-5.
11. Yanagisawa N, Kanazawa I, Goto I, Kowa H, Kuno S, Mizuno Y, Tashiro K, Ogawa N: Seven-year follow-up study of bromocriptine therapy for Parkinson’s disease, Eur Neurol 1994: 34(suppl 3):29-35.
12. Tashiro K, Goto I, Kanazawa I, Kowa H, Kuno S, Mizuno Y, Ogawa N, Yanagisawa N: Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease, Eur Neurol 1996:36(suppl l):32-37.
13. Kowa H, Kanazawa I, Goto I, Kuno S, Mizuno Y, Ogawa N, Tashiro K, Yanagisawa N: Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease, Eur Neurol 1997;38(suppl l):23-28.
14. Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, Manncn T, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N: A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease, Eur Neurol 1988:28(suppl 1):3-8.
15. Bakheit AMO, Henderson LM, Moore AP, Simpson JA, Thomas M: Long-term double masked trial of early treatment with -dopa plus bromocriptine versus ¿-dopa alone in Parkinson’s disease, Eur Neurol 1990:30:108-111.
16. Gawel M, Riopelle R, Libman I: Bromocriptine in the treatment of Parkinson's disease, A double-blind study against ¿-dopa/carbidopa, Adv Neurol 1986:45:535-538.
17. Hely MA, Morris JGL, Rail D, Reid WGJ, O'Sullivan DJ, Williamson PM, Gcngc S, Broe G: The Sydney multiccntre study of Parkinson’s disease: A report on the first 3 years, J Neurol Neurosurg Psychiatry 1989:52:324-328.
18. Przunlck H, Wclzel D, Gerlach M, Bliimner E, Danielczyk W, Kaiser H-J, Kraus PH, Letzel H, Riederer P, Oberla K: Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associatcd motor side effects, Long-term results of the PRADO study, J Neural Transm 1996;103:699-715.
19. Ogawa N, Edamatsu R, Mizukawa K, Asanu-ma M, Kohno M, Mori A: Degeneration of dopaminergic neurons and free radicals: Possible participation of levodopa, Adv Neurol 1993;60:242-250.
20. Kondo T, Ito T, Sugita Y: Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum, Neurobiology 1994:738:222- 229.
21. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A: Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro, Brain Res 1994;657:207-213.
22. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M: Antioxidant properties of bromocriptine, a dopamine agonist, J Neurochcm 1994; 62:1034-1038.
23. Cadet JL, Kahlcr LA: Free radical mechanisms in schizophrenia and tardivc dyskinesia, Ncu-rosci Biobehav Rev 1994:18:457-467.
24. Murata M, Mizusawa H, Yamanouchi H, Kanazawa I: Chronic levodopa therapy enhances dopa absorption: Contribution to wearing-off, J Neural Transm 1996:103:1177-1185.
25. Caine DB, Stocssl AJ: Transmitter receptor alterations in Parkinson’s disease, Adv Neurol 1986;45:45-49.
26. Guttman M, Seeman P: ,-Dopa reverses the elevated density of D2 dopamine receptors in Parkinson’s disease, J Neural Transm 1985:64: 93-103.
27. LcWitt RA: Levodopa therapeutics: New treatment strategies, Neurology 1993:43(suppl 6): S31-S37.
28. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM: Rationale for continuous dopaminomimetic therapy of Parkinson’s disease, Neurology 1989;39(suppl 2):7-10.
29. Rinne JO, Laihinen A, Nagres K, Bergman J, Solin O, Haaparanta M, Routsalaien U, Rinne UK: PET demonstrates different behaviour of striatal dopamine D-l and D-2 receptors in early Parkinson's disease, J Neurosci Res 1990; 27:494-499.
30. Lecnders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD: The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease, Arch Neurol 1990; 47:1290-1298.
31. Mouradian MM, Juncos JL, Fabbrini G, Schle-gel J, Bartko JJ, Case TN: Motor fluctuations in Parkinson’s disease: Central pathophysiological mechanism, part II, Ann Neurol 1988:24: 372-378.
32. Takahashi H, Tsujita M, Niwa M, Nagataki S: Effects of chronic administration of /-DOPA and bromocriptine on the dopaminergic metabolism in the striatum, Biogenic Amines 1987;4:15-22.
33. Adams JD Jr., Odunze IN: Oxygen free radicals and Parkinson's disease, Free Radie Biol Med 1991;10:161-169.
34. Cohen G: Monoamine oxidase, hydrogen peroxide, and Parkinson’s disease, Adv Neurol 1986;45:119-125.
35. Olanow CW: A radical hypothesis for neurodegeneration, TINS 1993:16:439-444.
36. Nishibayashi S, Asanuma M, Kohno M, G-mez-Vargas M, Ogawa N: Scavenging effects of dopamine agonists on nitric oxide radicals, J Neurochem 1996;67:2208-2211.
37. Tanaka M, Solomatsu A, Yoshida T, Hirai S: Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron, Neurosci Lett 1995:183:116-119.